In addition, different pharmacological treatments may be tested on this zebrafish model, including phosphodiesterase inhibitors (PDEIs) and receptor agonists (such as setmelanotide, a novel MC4R agonist recently approved for treating certain monogenic and syndromic obesity forms), expediting the development of novel therapies for use in humans. This evidence concerns the gene MC4R and Obesity.